ClinicalTrials.gg
Not yet recruitingNCT07601620Updated May 22, 2026

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer

A Phase 1 interventional study of HLX319 and EU-Phesgo® in HER2 + Breast Cancer, sponsored by Shanghai Henlius Biotech. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
258
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 13 studies in Breast Neoplasms by Fosun Pharma — 9 open to participants now, 10 under way, 4 of them phase 3. Breast Neoplasms · Fosun Pharma.

Planned enrollment
6th of 13
258 · median 180
Started
2026
with 5 others
Phase 1
3 of 13
2 open now
Registered
12th of 13
by date

Among the 13 studies in Breast Neoplasms by Fosun Pharma, this one is the 6th largest by planned enrollment, is one of 6 that started in 2026, is one of 3 in phase 1, and was the 12th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

9 of the 13 studies in Breast Neoplasms by Fosun Pharma are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Breast Neoplasms by Fosun Pharma, or all of them as a file.
02

Study summary

This is a study to compare the similarity in Pharmacokinetics (PK) profile of HLX319 vs. EU-Phesgo® in patients with HER2-positive early or locally advanced breast cancer .

Read the detailed description

This is a randomized, double-blind, parallel-controlled, multi-center Phase I equivalence study to compare the similarity in PK profile of HLX319 vs. EU-Phesgo® in patients with HER2-positive early or locally advanced breast cancer with a primary tumor > 2 cm or nodes-positive.

03

Conditions studied

  • HER2 + Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary participation in the clinical study and signed the Form (ICF).
  • Male or female aged ≥ 18 years old at the time of signing the ICF;
  • confirmed invasive breast cancer, stage II-IIIC, Human Epidermal Growth Factor Receptor 2 () positive confirmed by central laboratory.
  • Participants agree to undergo surgery while meeting the criteria for surgery after therapy.
  • (LVEF) at baseline ≥ 55%.
  • An (ECOG) performance status (PS) score of 0-1.
  • Adequate major organ functions.
  • Women with have a negative result of serum pregnancy test at screening period (within 7 days prior to the first dose) or if they are infertile, non- lactating, reproduction-age men and women following highly effective measures until 7 months after last dose.

Exclusion criteria

Exclusion Criteria:

  • Stage IV breast cancer, bilateral breast cancer, or multicentric breast cancer.
  • History of other within 5 years.
  • Prior systemic therapy for breast cancer treatment or radiotherapy.
  • Patients with a history of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) who have received systemic therapy or radiotherapy to the ipsilateral breast.
  • Patients who have undergone excision of the primary tumor and/or axillary lymph nodes or lymph node dissection.
  • Have severe heart disease or medical conditions.
  • Participants with viral hepatitis or those with hepatitis, sclerosing cholangitis, or liver cirrhosis.
  • (HIV) infection, HIV antibody positive.
  • Daily use of treatment is required.
  • Sensitivity to any study medications or any of its ingredients or .
  • Participants who underwent any major surgery within 28 days prior to the first dose. Or participants who have received local radiotherapy, radiofrequency ablation, or interventional therapy within 2 weeks prior to the first dose.
  • Received another interventional clinical trial therapy within 4 weeks prior to enrollment in the study, or intentionally participated in another interventional clinical trial during the entire study period.
  • Severe, uncontrolled systemic diseases that may currently interfere with the therapeutic plan.
  • Any other conditions which are inappropriate for the study in the opinion of the investigator.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
258 participants (estimated)

Study arms

  • Experimental
    HLX319

    The regimen in the experimental group is HLX319 in combination with docetaxel and carboplatin.

    Drug: HLX319

  • Active comparator
    EU-Phesgo®

    The regimen in the control group is EU-Phesgo® in combination with docetaxel and carboplatin.

    Drug: EU-Phesgo®

Interventions

  • DrugHLX319

    HLX319 is a biosimilar of pertuzumab-trastuzumab monoclonal antibody injection (subcutaneous injection)

  • DrugEU-Phesgo®

    EU-Phesgo® is an original marketed drug product, with the generic name pertuzumab-trastuzumab monoclonal antibody injection (subcutaneous injection)

This study also gives Trastuzumab, Pertuzumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Peak concentration (Cmax)

    Peak concentration after a single drug administration in Cycle 1.

    Time frame: up to 180 days

  2. Area under the serum drug concentration-time curve from 0 to 21 days (AUC0-21d)

    Area under the serum drug concentration-time curve from 0 to 21 days after a single drug administration in Cycle 1.

    Time frame: up to 180 days

  3. Steady-state peak concentration (Cmax,ss)

    The steady-state peak concentration after multiple doses administration in Cycle 4.

    Time frame: up to 180 days

  4. Steady-state area under the serum drug concentration-time curve within a dosing interval (AUCss)

    Steady-state area under the serum drug concentration-time curve within a dosing interval after multiple doses administration in Cycle 4.

    Time frame: up to 180 days

Secondary outcomes

  1. Trough concentration (Ctrough)

    Trough concentration after a single dose administration

    Time frame: up to 180 days

  2. Area under the serum drug concentration-time curve from time 0 to infinity (AUC0-inf)

    Area under the serum drug concentration-time curve from time 0 to infinity after a single dose administration

    Time frame: up to 180 days

  3. Percentage of extrapolated area in the total AUC (%AUCex)

    Percentage of extrapolated area in the total AUC after a single dose administration

    Time frame: up to 180 days

  4. Time to peak concentration (Tmax)

    time to peak concentration after a single dose administration

    Time frame: up to 180 days

  5. Elimination half-life (T1/2)

    elimination half-life after a single dose administration

    Time frame: up to 180 days

  6. Total clearance (CL/F)

    total clearance after a single dose administration

    Time frame: up to 180 days

  7. Terminal phase distribution volume (Vz/F)

    terminal phase distribution volume after a single dose administration

    Time frame: up to 180 days

  8. Mean residence time (MRT)

    mean residence time after a single dose administration

    Time frame: up to 180 days

  9. Steady-state trough concentration (Ctrough,ss)

    steady-state trough concentration after multiple doses administration in Cycle 4

    Time frame: up to 180 days

  10. Average steady-state concentration (Caverage,ss)

    average steady-state concentration after multiple doses administration in Cycle 4

    Time frame: up to 180 days

  11. Steady-state time to peak concentration (Tmax,ss)

    steady-state time to peak concentration after multiple doses administration in Cycle 4

    Time frame: up to 180 days

  12. Elimination half-life (T1/2,ss)

    elimination half-life after multiple doses administration in Cycle 4

    Time frame: up to 180 days

  13. Steady-state volume of distribution (Vss/F)

    steady-state volume of distribution after multiple doses administration in Cycle 4

    Time frame: up to 180 days

  14. Steady-state total clearance (CLss/F)

    steady-state total clearance after multiple doses administration in Cycle 4

    Time frame: up to 180 days

  15. accumulation ratio based on Cmax (RCmax)

    accumulation ratio based on Cmax after multiple doses administration in Cycle 4

    Time frame: up to 180 days

  16. Accumulation ratio based on AUC (RAUC)

    accumulation ratio based on AUC after multiple doses administration in Cycle 4

    Time frame: up to 180 days

  17. The total pathological complete response (tpCR) rate assessed by the investigator

    Time frame: up to 180 days

  18. Breast pathologic complete response (bpCR) rate assessed by the investigator

    Time frame: up to 180 days

  19. Objective response rate (ORR) assessed by the investigator

    according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria

    Time frame: up to 180 days

  20. Incidence and severity of adverse events (AEs)

    severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 6.0

    Time frame: up to 180 days

  21. Number of participants with abnormal vital signs

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: up to 180 days

  22. Number of participants with abnormal physical examination findings

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: up to 180 days

  23. Number of participants with abnormal Laboratory tests results

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: up to 180 days

  24. Number of participants with abnormal 12-lead ECG readings

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: up to 180 days

  25. Positivity rates of anti-drug antibodies (ADA)

    Time frame: up to 180 days

  26. Positivity rates of neutralizing antibodies (NAb)

    Time frame: up to 180 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Apr 2027, 9 months later.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 9 months is below that.

Counting every sponsor, half of 762 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2026
First posted
May 22, 2026
StartEst.
Jul 3, 2026
Primary completionEst.
Apr 23, 2027
CompletionEst.
Jul 22, 2027
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07601620
Responsible party
Sponsor
First posted
May 22, 2026
Start date
Jul 3, 2026 (estimated)
Primary completion
Apr 23, 2027 (estimated)
Completion
Jul 22, 2027 (estimated)
Last update
May 22, 2026

Study contacts

Qi Jin
Contact
Qi_jin@henlius.com
86 159 5516 0489

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion